Cargando…

Immunocytochemical Characterization of Alzheimer’s Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine

INTRODUCTION: APP/PS1 double-transgenic mouse models of Alzheimer’s disease (AD), which overexpress mutated forms of the gene for the human amyloid precursor protein (APP) and presenilin 1 (PS1), have provided robust neuropathological hallmarks of an AD-like pattern at early ages. This study aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrera, Ivan, Etcheverria, Ignacio, Li, Yi, Fernandez-Novoa, Lucia, Lombardi, Valter, Vigo, Carmen, Palacios, Hector H., Benberin, Valery V., Cacabelos, Ramon, Aliev, Gjumrakch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University Library System, University of Pittsburgh 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960902/
https://www.ncbi.nlm.nih.gov/pubmed/29805876
http://dx.doi.org/10.5195/cajgh.2013.119
_version_ 1783324660836859904
author Carrera, Ivan
Etcheverria, Ignacio
Li, Yi
Fernandez-Novoa, Lucia
Lombardi, Valter
Vigo, Carmen
Palacios, Hector H.
Benberin, Valery V.
Cacabelos, Ramon
Aliev, Gjumrakch
author_facet Carrera, Ivan
Etcheverria, Ignacio
Li, Yi
Fernandez-Novoa, Lucia
Lombardi, Valter
Vigo, Carmen
Palacios, Hector H.
Benberin, Valery V.
Cacabelos, Ramon
Aliev, Gjumrakch
author_sort Carrera, Ivan
collection PubMed
description INTRODUCTION: APP/PS1 double-transgenic mouse models of Alzheimer’s disease (AD), which overexpress mutated forms of the gene for the human amyloid precursor protein (APP) and presenilin 1 (PS1), have provided robust neuropathological hallmarks of an AD-like pattern at early ages. This study aimed to characterize immunocytochemical patterns of the AD mouse brain, which is treated with the EB101 vaccine, as a model for human AD. MATERIAL AND METHODS: In this novel vaccine, a new approach has been taken to circumvent past failures with Aβ vaccines by judiciously selecting an adjuvant consisting of a physiological matrix embedded in liposomes, composed of naturally occurring phospholipids (phosphatidylcholine, phosphatidylglycerol, and cholesterol). RESULTS: Our findings showed that the administration of amyloid-β1–42 (Aβ) and sphingosine-1-phosphate emulsified in liposome complex (EB101) to APP/PS1 mice before the onset of Aβ brain deposition (at 7 weeks of age) and/or at an older age (35 weeks of age) can be effective in both halting the progression and clearing the AD-like neuropathological hallmarks. In addition, passive immunization with EB101 did not activate inflammatory responses from the immune system and astrocytes. Consistent with a decreased inflammatory background, the basal immunological interaction between the T cells and the affected areas (hippocampus) in the brain of treated mice was notably reduced. CONCLUSION: These results provide strong evidence that immunization with the EB101 vaccine prevents and attenuates AD neuropathology in this type of double-transgenic mice.
format Online
Article
Text
id pubmed-5960902
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher University Library System, University of Pittsburgh
record_format MEDLINE/PubMed
spelling pubmed-59609022018-05-25 Immunocytochemical Characterization of Alzheimer’s Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine Carrera, Ivan Etcheverria, Ignacio Li, Yi Fernandez-Novoa, Lucia Lombardi, Valter Vigo, Carmen Palacios, Hector H. Benberin, Valery V. Cacabelos, Ramon Aliev, Gjumrakch Cent Asian J Glob Health Articles INTRODUCTION: APP/PS1 double-transgenic mouse models of Alzheimer’s disease (AD), which overexpress mutated forms of the gene for the human amyloid precursor protein (APP) and presenilin 1 (PS1), have provided robust neuropathological hallmarks of an AD-like pattern at early ages. This study aimed to characterize immunocytochemical patterns of the AD mouse brain, which is treated with the EB101 vaccine, as a model for human AD. MATERIAL AND METHODS: In this novel vaccine, a new approach has been taken to circumvent past failures with Aβ vaccines by judiciously selecting an adjuvant consisting of a physiological matrix embedded in liposomes, composed of naturally occurring phospholipids (phosphatidylcholine, phosphatidylglycerol, and cholesterol). RESULTS: Our findings showed that the administration of amyloid-β1–42 (Aβ) and sphingosine-1-phosphate emulsified in liposome complex (EB101) to APP/PS1 mice before the onset of Aβ brain deposition (at 7 weeks of age) and/or at an older age (35 weeks of age) can be effective in both halting the progression and clearing the AD-like neuropathological hallmarks. In addition, passive immunization with EB101 did not activate inflammatory responses from the immune system and astrocytes. Consistent with a decreased inflammatory background, the basal immunological interaction between the T cells and the affected areas (hippocampus) in the brain of treated mice was notably reduced. CONCLUSION: These results provide strong evidence that immunization with the EB101 vaccine prevents and attenuates AD neuropathology in this type of double-transgenic mice. University Library System, University of Pittsburgh 2014-03-27 /pmc/articles/PMC5960902/ /pubmed/29805876 http://dx.doi.org/10.5195/cajgh.2013.119 Text en New articles in this journal are licensed under a Creative Commons Attribution 3.0 License (https://creativecommons.org/licenses/by/3.0/) .
spellingShingle Articles
Carrera, Ivan
Etcheverria, Ignacio
Li, Yi
Fernandez-Novoa, Lucia
Lombardi, Valter
Vigo, Carmen
Palacios, Hector H.
Benberin, Valery V.
Cacabelos, Ramon
Aliev, Gjumrakch
Immunocytochemical Characterization of Alzheimer’s Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
title Immunocytochemical Characterization of Alzheimer’s Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
title_full Immunocytochemical Characterization of Alzheimer’s Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
title_fullStr Immunocytochemical Characterization of Alzheimer’s Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
title_full_unstemmed Immunocytochemical Characterization of Alzheimer’s Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
title_short Immunocytochemical Characterization of Alzheimer’s Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
title_sort immunocytochemical characterization of alzheimer’s disease hallmarks in app/ps1 transgenic mice treated with a new anti-amyloid-β vaccine
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960902/
https://www.ncbi.nlm.nih.gov/pubmed/29805876
http://dx.doi.org/10.5195/cajgh.2013.119
work_keys_str_mv AT carreraivan immunocytochemicalcharacterizationofalzheimersdiseasehallmarksinappps1transgenicmicetreatedwithanewantiamyloidbvaccine
AT etcheverriaignacio immunocytochemicalcharacterizationofalzheimersdiseasehallmarksinappps1transgenicmicetreatedwithanewantiamyloidbvaccine
AT liyi immunocytochemicalcharacterizationofalzheimersdiseasehallmarksinappps1transgenicmicetreatedwithanewantiamyloidbvaccine
AT fernandeznovoalucia immunocytochemicalcharacterizationofalzheimersdiseasehallmarksinappps1transgenicmicetreatedwithanewantiamyloidbvaccine
AT lombardivalter immunocytochemicalcharacterizationofalzheimersdiseasehallmarksinappps1transgenicmicetreatedwithanewantiamyloidbvaccine
AT vigocarmen immunocytochemicalcharacterizationofalzheimersdiseasehallmarksinappps1transgenicmicetreatedwithanewantiamyloidbvaccine
AT palacioshectorh immunocytochemicalcharacterizationofalzheimersdiseasehallmarksinappps1transgenicmicetreatedwithanewantiamyloidbvaccine
AT benberinvaleryv immunocytochemicalcharacterizationofalzheimersdiseasehallmarksinappps1transgenicmicetreatedwithanewantiamyloidbvaccine
AT cacabelosramon immunocytochemicalcharacterizationofalzheimersdiseasehallmarksinappps1transgenicmicetreatedwithanewantiamyloidbvaccine
AT alievgjumrakch immunocytochemicalcharacterizationofalzheimersdiseasehallmarksinappps1transgenicmicetreatedwithanewantiamyloidbvaccine